NovoCure

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

CEO

Ashley Cordova

CEOAshley Cordova

Employees

1,488

Employees1,488

Headquarters

St. Helier, Jersey

HeadquartersSt. Helier, Jersey

Founded

2000

Founded2000

Employees

1,488

Employees1,488

NVCR Key Statistics

Market cap

1.57B

Market cap1.57B

Price-Earnings ratio

-9.29

Price-Earnings ratio-9.29

Dividend yield

—

Dividend yield—

Average volume

2.34M

Average volume2.34M

High today

$14.62

High today$14.62

Low today

$13.94

Low today$13.94

Open price

$14.50

Open price$14.50

Volume

678.51K

Volume678.51K

52 Week high

$34.13

52 Week high$34.13

52 Week low

$10.87

52 Week low$10.87

NVCR News

Simply Wall St 3d

NovoCure: Assessing Valuation After Positive Phase 3 METIS Trial Results Unveiled

NovoCure (NVCR) stock is on the move after the company published final data from its pivotal Phase 3 METIS trial. The results, presented at the ASTRO Annual Mee...

Simply Wall St 4d

Why NovoCure Is Up 9.9% After Phase 3 METIS Trial Success in Brain Metastases

Novocure announced that final results from its Phase 3 METIS trial showed Tumor Treating Fields (TTFields) therapy combined with best supportive care significan...

Analyst ratings

63%

of 8 ratings

Buy

62.5%

Hold

37.5%

Sell

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.